Keywords

chronic kidney disease, diabetes, diabetic kidney disease, glomerular filtration rate, hypertension, NKF-ASN task force, race and eGFR, SGLT2 inhibitors

Authors

1. Mead, Daniel DNP, APRN-FPA, AGNP-C, CNN-NP, CHSE
2. Dinh, Nhan MSN, CNP, AGACNP-BC
3. Wentworth, Danielle MSN, FNP-BC
4. Thomas, Sofia DNP, MSN, MHA, APRN, CNN-NP, FNP-C, CPH, FNKF
5. Suthar, Meera MSN, FNP-C, CNN-NP

Abstract

Abstract: Since 2020, several guidelines have been published to help health practitioners better manage hypertension and diabetes in patients with chronic kidney disease. Scrutiny on the inclusion of race in determining the estimated glomerular filtration rate (eGFR) as well as breakthrough research regarding the drug dapagliflozin for the treatment of patients with chronic kidney disease are discussed.